PubMed Health⌕ Search

PubMed · 3992122

[Estrogens and the endometrium].

Abstract

A large number of studies have drawn attention to the multiplication of the number of endometrial cancers in women under oestrogens. All these retrospective studies are concordant, but the majority can be the object of criticisms and do not necessarily carry conviction. Oestroprogestational associations seem, on the contrary, to protect, in a certain measure, against the appearance of carcinoma of the endometrium. The author concludes that, in the uncertainty, it is indubitably necessary not to establish as a principle that the menopause should be treated with oestrogens, but to give under surveillance the necessary oestrogen treatment to women who need them. One should take care to choose an oestrogen as natural as possible, and it is desirable to associate it with progesterone.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Y Rochet. 1985. [Estrogens and the endometrium].. https://pubmed.ncbi.nlm.nih.gov/3992122/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

[Revision of the recommendations of the Commission on Pharmacotherapy of the German Society for Rheumatology. Comment on the use of mycophenolic acid for systemic lupus erythematosus].

According to the NIH scheme, the "evidence based medicine" standard in the treatment of severe proliferative lupus-nephritis is cyclophosphamide in combination with steroids. Undesired effects, therapy resistance, and deficient long-term effects underscore the necessity for the development of alternative therapies for the treatment of organ involvement. Mycophenolate mofetil (MMF) possesses the potential to decisively improve the therapeutic possibilities for systemic lupus erythematosus (SLE). On the basis of the available data, MMF represents an alternative to the current standard therapies for severe lupus-nephritises and shows less toxicity. MMF is also effective in patients with other manifestations refractory to conventional therapy. Questions remain unanswered on the optimal dosage and possible reduction in cases of remission. In addition, the duration of maintenance therapy is unclear. Therefore, large, prospective, randomized clinical studies in the treatment of lupus-nephritis with a sufficiently long follow-up phase are underway.

Drug Therapy, Combination↗